Navigation Links
Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:2/1/2008

CRANBURY, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York, NY on Thursday, February 7, 2008 at 11:40 am (Eastern Standard Time) at the Grand Hyatt Hotel.

The presentation will be webcast live and may be accessed by visiting Amicus' website at http://www.amicustherapeutics.com. A replay of the webcast will also be available on the Company's website until February 22, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company has completed Phase 1 clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities L
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
2. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
3. Amicus Therapeutics to Host R&D Day
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
6. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
7. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
8. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
9. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
10. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
11. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Diego, California (PRWEB) January 22, 2015 ... Promotional Offer to their comprehensive portfolio of Eppendorf ... allows customers to purchase a Centrifuge 5424/5424 R and ... Bundle of either Eppendorf Research plus or Eppendorf Reference ...
(Date:1/22/2015)... January 22, 2015 Dr. Greg Leyer of ... annual Scripps Natural Supplements Pre-Conference seminar on probiotics in San ... an annual continuing education conference for health care professionals. This ... the topic of probiotics in health. Dr. Leyer spoke about ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... 2011 EdeniQ, Inc. , a California-based clean ... that it has licensed yeast technology from the USDA ... Foundation (WARF) associated with the fermentation of C5 sugars, ... culmination of the 3-year Cooperative Research and Development Agreement ...
... June 14, 2011 Arcion Therapeutics , a ... for chronic pain, today announced that data from the ... pain associated with painful diabetic neuropathy (PDN) will be ... meetings.  The first poster will be presented at the ...
... PAREXEL International Corporation (NASDAQ: PRXL ... Wells Fargo Healthcare Conference in Boston, MA.  James Winschel, Sr. ... presentation on PAREXEL at 2:00 p.m. ET on Wednesday, June ... will be available through the "Investors" section of ...
Cached Biology Technology:EdeniQ Licenses Yeast Technology from USDA 2Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 2Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 3PAREXEL International to Present at Wells Fargo Healthcare Conference 2
(Date:1/22/2015)... 2015   EyeLock, Inc. , a market leader of iris-based ... Gerber to the new role of Senior Vice President ... development of mobile platforms and wearable solutions for EyeLock,s technologies. ... in the semiconductor industry to his role at EyeLock, with ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... common gene mutation found in acute myeloid leukaemia starts ... cooperate with a well-defined group of other mutations to ... critical steps are required to transform normal blood cells ... By charting the route towards cancer, the study identifies ...
... to handle, but when you chase it with prolonged oxygen ... last millions of years. Such was the situation with ... ago, when 90 percent of all marine animal species were ... and insect species on land. A massive amount of ...
... Hamilton schools has identified energy conservation measures that ... million annually. The audit was conducted by engineering ... measures, presented today to officials from the Hamilton-Wentworth ... School Board, range from recaulking windows, adding insulation ...
Cached Biology News:The gene processes that drive acute myeloid leukaemia 2The gene processes that drive acute myeloid leukaemia 3Algae, bacteria hogged oxygen after ancient mass extinction, slowed marine life recovery 2Algae, bacteria hogged oxygen after ancient mass extinction, slowed marine life recovery 3Algae, bacteria hogged oxygen after ancient mass extinction, slowed marine life recovery 4School energy audits find millions in potential energy savings 2School energy audits find millions in potential energy savings 3
... (bluish-purple), DNA (blue), proteins (red) and acid polysaccharides ... traces: Ca ≤ 10 mg/kg Cd ≤ 5 mg/kg ... ≤ 5 mg/kg Fe ≤ 5 mg/kg K ≤ ... mg/kg Na ≤ 50 mg/kg Ni ≤ 5 mg/kg ...
BioGenex IHC Kits for Rodent Tissues are designed for immunohistochemistry on rodent and rabbit tissues that are closely related to the source of the primary antibody. This kit comes with rat seconda...
... The BioGenex Super Sensitive ... is a novel product ... non-biotin polymeric technology. This ... signal to noise ratio ...
... The dual-bay DNA Engine Dyad ... for DNA amplification (PCR). The chassis ... units (sample-holder, heat-pump assemblies), which hold ... Color display offers graphical programming with ...
Biology Products: